Surface Oncology reins back its lead program after tracking low-dose toxicity for CD47 drug
Surface Oncology’s lead drug — an anti-CD47 antibody — has run into some heavy turbulence, and the Cambridge, MA-based biotech is buckling up for a rough ride.
After the market closed Tuesday the company $SURF put out word that SRF231’s early-stage human study was being curtailed.
During the dose escalation portion of the phase 1, two hematologic dose-limiting toxicities (DLTs) were seen at a lower dose (12 mg/kg) than anticipated and resolved without long-term toxicity. Surface will explore additional dose administration schedules but will not open expansion cohorts in the phase 1 study.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.